The company aims to streamline its own lab operations while also enabling distribution of its Alzheimer's tests to outside labs both in the US and abroad.
Zishan Alvi submitted claims to the US Department of Health and Human Services’ Health Resources and Services Administration for COVID-19 tests not performed as billed.
Of the 30 companies in the index, 13 saw their stock prices increase, 15 saw their share prices decline, and two firms' stock prices remained essentially flat.
A hospital, a laboratory, three lab employees, and a referring physician and his office manager have agreed to pay more than $7.2 million dollars to resolve lab fraud allegations.
Within three years, the project anticipates at least one test for the early-stage detection of Alzheimer's disease could be ready for commercialization.
The Cambridge, UK-based firm said that the project will help it to develop its breath-based tests and support the development of tools for breath-based testing.